Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Towards Immunotherapy for Pediatric Brain Tumors.

Wang SS, Bandopadhayay P, Jenkins MR.

Trends Immunol. 2019 Jun 19. pii: S1471-4906(19)30123-1. doi: 10.1016/j.it.2019.05.009. [Epub ahead of print] Review.

2.

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

Ishikawa E, Yamamoto T, Matsumura A.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24. Review.

3.

Immunotherapy for brain tumors: understanding early successes and limitations.

Lieberman NAP, Vitanza NA, Crane CA.

Expert Rev Neurother. 2018 Mar;18(3):251-259. doi: 10.1080/14737175.2018.1425617. Epub 2018 Jan 11. Review.

PMID:
29322843
4.

DIPG in Children - What Can We Learn from the Past?

Vanan MI, Eisenstat DD.

Front Oncol. 2015 Oct 21;5:237. doi: 10.3389/fonc.2015.00237. eCollection 2015. Review.

5.

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL.

Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.

6.

Immunotherapy approaches in the treatment of malignant brain tumors.

Dunn-Pirio AM, Vlahovic G.

Cancer. 2017 Mar 1;123(5):734-750. doi: 10.1002/cncr.30371. Epub 2016 Nov 22. Review.

7.

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H.

Front Immunol. 2019 Jan 22;9:3062. doi: 10.3389/fimmu.2018.03062. eCollection 2018. Review.

8.

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.

Petersen CT, Krenciute G.

Front Oncol. 2019 Feb 26;9:69. doi: 10.3389/fonc.2019.00069. eCollection 2019. Review.

9.

Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.

Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB.

Anticancer Res. 2013 May;33(5):2047-56.

10.

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.

Filley AC, Henriquez M, Dey M.

Front Oncol. 2018 Oct 17;8:453. doi: 10.3389/fonc.2018.00453. eCollection 2018. Review.

11.

Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW.

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29861325
12.

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.

Kosti P, Maher J, Arnold JN.

Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018. Review.

13.

Immunotherapy for Pediatric Brain Tumors.

Sayour EJ, Mitchell DA.

Brain Sci. 2017 Oct 21;7(10). pii: E137. doi: 10.3390/brainsci7100137. Review.

14.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

15.

Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.

Yazdanifar M, Zhou R, Mukherjee P.

Curr Trends Immunol. 2016;17:95-115.

16.

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.

Ring EK, Markert JM, Gillespie GY, Friedman GK.

Clin Cancer Res. 2017 Jan 15;23(2):342-350. doi: 10.1158/1078-0432.CCR-16-1829. Epub 2016 Nov 10. Review.

17.

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R.

Neuro Oncol. 2016 Apr;18(4):518-27. doi: 10.1093/neuonc/nov173. Epub 2015 Sep 26.

18.

New developments in immunotherapy for pediatric solid tumors.

Schultz LM, Majzner R, Davis KL, Mackall C.

Curr Opin Pediatr. 2018 Feb;30(1):30-39. doi: 10.1097/MOP.0000000000000564. Review.

PMID:
29189429
19.
20.

Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.

Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones DT, Hovestadt V, Marshall LV, Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton R, Al-Sarraj S, Pfister SM, Leach MO, Pearson AD, Jones C, Koh DM, Zacharoulis S.

J Neurooncol. 2016 Aug;129(1):109-21. doi: 10.1007/s11060-016-2151-8. Epub 2016 May 14.

PMID:
27180091

Supplemental Content

Support Center